benserazide has been researched along with Cerebellar Ataxia in 5 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
Cerebellar Ataxia: Incoordination of voluntary movements that occur as a manifestation of CEREBELLAR DISEASES. Characteristic features include a tendency for limb movements to overshoot or undershoot a target (dysmetria), a tremor that occurs during attempted movements (intention TREMOR), impaired force and rhythm of diadochokinesis (rapidly alternating movements), and GAIT ATAXIA. (From Adams et al., Principles of Neurology, 6th ed, p90)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A quantitative evaluation of cerebellar ataxia, with an ataxia score (total, static, kinetic) and the measurement of objective values relating to the major symptoms, was used in 21 patients with hereditary ataxias treated for 12 months with high doses (16 mg/kg/day) of d-l-5-HTP, l-5-HTP or the combination d-l-5-HTP (16 mg/kg/day)--benserazide (6 mg/kg/day)." | 7.67 | Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide. ( Trouillas, P, 1984) |
| "A quantitative evaluation of cerebellar ataxia, with an ataxia score (total, static, kinetic) and the measurement of objective values relating to the major symptoms, was used in 21 patients with hereditary ataxias treated for 12 months with high doses (16 mg/kg/day) of d-l-5-HTP, l-5-HTP or the combination d-l-5-HTP (16 mg/kg/day)--benserazide (6 mg/kg/day)." | 3.67 | Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide. ( Trouillas, P, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Trouillas, P | 4 |
| Garde, A | 2 |
| Robert, JM | 2 |
| Adeleine, P | 2 |
| Renaud, B | 1 |
| Bard, J | 1 |
| Brudon, F | 1 |
| Klein, P | 1 |
| Lees, A | 1 |
| Stern, G | 1 |
1 trial available for benserazide and Cerebellar Ataxia
| Article | Year |
|---|---|
Cerebeller ataxia.
Topics: 5-Hydroxytryptophan; Benserazide; Cerebellar Ataxia; Clinical Trials as Topic; Drug Therapy, Combina | 1990 |
4 other studies available for benserazide and Cerebellar Ataxia
| Article | Year |
|---|---|
Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide.
Topics: 5-Hydroxytryptophan; Benserazide; Cerebellar Ataxia; Dopamine; Drug Therapy, Combination; Friedreich | 1984 |
[Regression of human cerebellar ataxia under long term administration of 5-hydroxytryptophan].
Topics: 5-Hydroxytryptophan; Adult; Benserazide; Cerebellar Ataxia; Female; Friedreich Ataxia; Humans; Male; | 1981 |
[Regression of the cerebellar syndrome under long-term administration of 5-HTP or the combination of 5-HTP and benserazide. 26 cases quantified and treated using computer methods].
Topics: 5-Hydroxytryptophan; Benserazide; Cerebellar Ataxia; Computers; Drug Therapy, Combination; Humans; H | 1982 |
Consequences of chronic 5-hydroxy-tryptophan in parkinsonian instability of gait and balance and in other neurological disorders.
Topics: 5-Hydroxytryptophan; Adult; Aged; Benserazide; Cerebellar Ataxia; Drug Therapy, Combination; Female; | 1987 |